Triomics, a San Francisco, CA-based company advancing generative AI models to streamline workflows for cancer centers, raised $15M in funding.
Backers included Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator.
The company intends to use the funds to expand operations and its development efforts.
Led by Sarim Khan (CEO) and Hrituraj Singh (CTO), Triomics develops oncology-specialized generative AI models (OncoLLMTM) and use case-specific software to help cancer providers process free-text health record data at scale, match patients to clinical trials, improve quality of care operations and deliver precision oncology.
Its OncoLLM™ empowers proprietary software that integrates with health system EHRs to complete specific clinical and administrative tasks. For example, Triomics Prism aids in patient-trial matching by prescreening oncology patients with upcoming appointments to find relevant clinical trials. Triomics Harmony curates EHR data to support quality reporting, cohort analysis and precision oncology.
Next, Triomics plans to publish additional data on OncoLLM efficacy across a diversity of settings and patient populations, and develop software that powers additional use cases.
Commenting on the news, Hrituraj Singh said: “Our investments in our core areas of focus have been deliberate. We have successfully merged expertise in two complex functional areas: our AI researchers, who are specialized in customizing language models to specific domains, and our clinical staff, who have decades of oncology-specific experience. As a result, our software can complement the strengths of these advanced models while also proactively addressing potential flaws, all with the intricacies of cancer research and care in mind.”
